UB
TVTX icon

UMB Bank’s Travere Therapeutics TVTX Stock Holding History

UMB Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-310
Closed -$8K – 1835
2022
Q3 		$8K Hold
310
– – ﹤0.01% 1382
2022
Q2 		$8K Hold
310
– – ﹤0.01% 1467
2022
Q1 		$8K Hold
310
– – ﹤0.01% 1557
2021
Q4 		$10K Buy
+310
New +$8.73K ﹤0.01% 1460

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UMB Bank's TVTX Position: Q4 2022 in Review

UMB Bank sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 310 shares — an estimated $8K sold.

UMB Bank first reported a position in TVTX in Q4 2021 and held it in 4 quarters. The position peaked at $10K in Q4 2021. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

  • UMB Bank reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
  • UMB Bank sold 310 Travere Therapeutics shares in Q4 2022, an estimated $8K.
  • UMB Bank first reported a position in Travere Therapeutics in Q4 2021 and held it in 4 quarters.
  • UMB Bank's Travere Therapeutics position peaked at $10K in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on UMB Bank's 13F filing for Q4 2022, filed 10 Jan 2023.